Undetectable ctDNA at baseline correlates with favorable outcomes in patients with CNSL. (A) Comparison of FFS between patients with undetectable ctDNA at baseline (blue solid line) and patients with detectable ctDNA at baseline (red dashed line; n = 67 patients). (B) Comparison of PFS between patients with undetectable ctDNA at baseline (blue solid line) and patients with detectable ctDNA at baseline (red dashed line; n = 67 patients). (C) Comparison of OS between patients with undetectable ctDNA at baseline (blue solid line) and patients with detectable ctDNA at baseline (red dashed line; n = 67 patients). (D) Bar plot comparing the fraction of patients suffering from relapse between patients with detectable ctDNA at baseline (blue) and patients with undetectable ctDNA at baseline (red). (E) Bar plot comparing the fraction of patients that died between patients with detectable ctDNA at baseline (blue) and patients with undetectable ctDNA at baseline (red). Statistical significance was assessed using log-rank tests.